Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change -0.57
Percentage change -1.03	%

Peers: VRTX BIIB REGN AMGN GILD NBIX INCY ALNY EXEL IONS

| Held by: IJH VTI IWM VB XBI VXF VBK XMHQ IWO MDY

Index	RUT	P/E	18.13	EPS (ttm)	3.02	Insider Own	1.05%	Shs Outstand	127.18M	Perf Week	3.79%
Market Cap	6.97B	Forward P/E	10.85	EPS next Y	5.05	Insider Trans	-14.95%	Shs Float	125.89M	Perf Month	14.10%
Income	392.47M	PEG	-	EPS next Q	1.16	Inst Own	99.53%	Short Float	7.55%	Perf Quarter	2.51%
Sales	947.36M	P/S	7.36	EPS this Y	49.04%	Inst Trans	2.48%	Short Ratio	5.64	Perf Half Y	0.92%
Book/sh	3.56	P/B	15.40	EPS next Y	22.37%	ROA	19.57%	Short Interest	9.50M	Perf Year	52.05%
Cash/sh	5.24	P/C	10.46	EPS next 5Y	-	ROE	111.83%	52W Range	33.15 - 65.53	Perf YTD	14.62%
Dividend Est.	-	P/FCF	17.75	EPS past 5Y	-	ROI	20.06%	52W High	-16.38%	Beta	1.24
Dividend TTM	-	Quick Ratio	9.15	Sales past 5Y	44.18%	Gross Margin	74.59%	52W Low	65.31%	ATR (14)	1.64
Dividend Ex-Date	-	Current Ratio	10.36	EPS Y/Y TTM	61.49%	Oper. Margin	50.35%	RSI (14)	67.38	Volatility	2.84% 3.05%
Employees	373	Debt/Eq	3.32	Sales Y/Y TTM	21.35%	Profit Margin	41.43%	Recom	2.00	Target Price	64.75
Option/Short	Yes / Yes	LT Debt/Eq	3.32	EPS Q/Q	72.51%	Payout	0.00%	Rel Volume	0.56	Prev Close	55.37
Sales Surprise	15.03%	EPS Surprise	28.11%	Sales Q/Q	34.28%	Earnings	Oct 31 AMC	Avg Volume	1.69M	Price	54.80
SMA20	9.12%	SMA50	8.58%	SMA200	7.36%	Trades		Volume	942,027	Change	-1.03%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-07-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$58 → $62
Sep-19-24	Downgrade	JP Morgan	Overweight → Neutral	$52 → $57
Jun-07-24	Downgrade	Piper Sandler	Overweight → Neutral	$48 → $51
Feb-29-24	Initiated	TD Cowen	Outperform	$54
Jul-24-23	Initiated	H.C. Wainwright	Buy	$61
Jul-24-23	Downgrade	Goldman	Buy → Neutral	$43 → $45
May-10-23	Upgrade	Piper Sandler	Neutral → Overweight	$46
Mar-27-23	Resumed	Berenberg	Buy	$58
Mar-16-23	Downgrade	SVB Securities	Outperform → Market Perform	$42
Dec-21-22	Resumed	Morgan Stanley	Overweight	$53 → $65
Nov-28-22	Initiated	Wells Fargo	Overweight	$65
Sep-09-22	Initiated	Morgan Stanley	Overweight	$50
May-23-22	Initiated	SVB Leerink	Outperform	$52
Jun-14-21	Initiated	Evercore ISI	Outperform
May-17-21	Initiated	SVB Leerink	Outperform	$56
May-11-21	Downgrade	Piper Sandler	Overweight → Neutral	$50 → $48
Jan-21-21	Reiterated	The Benchmark Company	Buy	$46 → $59
Dec-17-20	Initiated	Berenberg	Buy	$50
Sep-14-20	Resumed	JP Morgan	Overweight	$28
Jul-01-20	Initiated	The Benchmark Company	Buy	$39

Show Previous Ratings

Jan-15-25 03:44PM	BeiGene Stock Meets 80-Plus RS Rating Benchmark (Investor's Business Daily)
Jan-14-25 03:30PM	BridgeBio Pharma Stock Earns 87 RS Rating (Investor's Business Daily)
Jan-10-25 12:45PM	Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
Jan-09-25 08:52AM	Are Options Traders Betting on a Big Move in Halozyme (HALO) Stock? (Zacks)
Jan-08-25 02:54PM	SpringWorks Therapeutics Stock Gets A RS Rating Lift (Investor's Business Daily) +5.02%
07:43AM	Loading…
07:43AM	Halozyme Preliminary 2024 Estimated Ranges Consistent With Guidance; Raises FY25 Guidance (RTT News)
07:00AM	Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance (PR Newswire)
Jan-06-25 08:30AM	Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance (PR Newswire) +5.80%
Dec-30-24 07:00AM	Halozyme Announces Takeda Received Regulatory Approval for HYQVIA 10% Subcutaneous Injection Set with ENHANZE in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia (PR Newswire)
06:45AM	Halozyme Announces argenx's VYDURA with ENHANZE was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy (PR Newswire)
06:30AM	Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig with ENHANZE for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo (nivolumab) Indications (PR Newswire)
Dec-23-24 12:45PM	3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO) (Zacks)
Dec-16-24 09:55AM	How Much Upside is Left in Halozyme Therapeutics (HALO)? Wall Street Analysts Think 27.08% (Zacks)
Dec-11-24 09:40AM	Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy? (Zacks)
Dec-09-24 09:45AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock (Zacks)
09:40AM	Loading…
09:40AM	Is Halozyme Therapeutics (HALO) Stock Undervalued Right Now? (Zacks)
Dec-05-24 12:45PM	Here is Why Growth Investors Should Buy Halozyme Therapeutics (HALO) Now (Zacks)
09:40AM	Is Halozyme Therapeutics (HALO) Outperforming Other Medical Stocks This Year? (Zacks)
Nov-27-24 08:30AM	Halozyme to Present at Upcoming Investor Conferences (PR Newswire)
Nov-22-24 12:12PM	Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook (Benzinga) +7.22%
12:00PM	Halozyme Therapeutics (HALO) Upgraded to Buy: Here's Why (Zacks)
09:45AM	Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term (Zacks)
09:21AM	Halozyme shares jump 12% as it scraps $2.1 bln Evotec deal (Investing.com)
08:35AM	Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions (PR Newswire)
05:30AM	Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial (BioPharma Dive)
Nov-21-24 09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Nov-19-24 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO) (Zacks) +5.26%
09:40AM	Is Halozyme Therapeutics (HALO) a Great Value Stock Right Now? (Zacks)
Nov-18-24 07:00AM	Halozyme Provides Update on Non-Binding Proposal to Combine with Evotec (PR Newswire) -6.75%
Nov-17-24 05:24PM	Halozyme to Fund Proposed Evotec Takeover in Cash, CEO Says (Bloomberg)
12:56PM	Loading…
Nov-15-24 12:56PM	Large Pharma Partner Halozyme Therapeutics Offers To Acquire Germany-Based Evotec For ~$2 Billion (Benzinga) -15.40%
09:50AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock (Zacks)
05:11AM	Evotec shares surge 20% on Halozyme's 2 billion euro takeover bid (Investing.com)
05:00AM	Halozyme bids for Evotec; BeiGene gets a new name (BioPharma Dive)
03:36AM	Germanys Evotec Gets Takeover Interest From Halozyme (Bloomberg)
Nov-14-24 04:15PM	Halozyme Confirms Proposal to Combine with Evotec for 11.00 Per Share in an All-Cash Transaction (PR Newswire) -7.93%
Nov-04-24 09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Nov-01-24 11:42AM	Halozyme Announces Record Earnings, Guidance (FX Empire) +13.01%
03:18AM	Halozyme Therapeutics Inc (HALO) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Oct-31-24 05:30PM	Halozyme Therapeutics (HALO) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
05:15PM	Halozyme Therapeutics (HALO) Beats Q3 Earnings and Revenue Estimates (Zacks)
04:10PM	Halozyme Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS (PR Newswire)
Oct-24-24 06:30AM	HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE (PR Newswire)
Oct-23-24 04:30PM	Halozyme to Report Third Quarter 2024 Financial and Operating Results (PR Newswire)
Oct-17-24 01:02PM	State Street Corp's Strategic Acquisition in Halozyme Therapeutics Inc (GuruFocus.com)
09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)
Oct-14-24 09:35AM	Implied Volatility Surging for Halozyme Therapeutics (HALO) Stock Options (Zacks)
Oct-07-24 12:10PM	Why Halozyme Therapeutics (HALO) Could Beat Earnings Estimates Again (Zacks) -9.01%
Oct-03-24 08:00AM	Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx for ENHANZE (PR Newswire)
Sep-20-24 11:08AM	Global Cancer Rates Surge as Biotech Innovators Work on New Therapies (PR Newswire)
Sep-16-24 06:33AM	FDA approves Roches Ocrevus Zunovo with Halozyme Enhanze delivery tech (Pharmaceutical Technology)
Sep-13-24 01:30PM	Halozyme Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE for People with Relapsing and Primary Progressive Multiple Sclerosis (PR Newswire)
Sep-12-24 08:00PM	Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza With ENHANZE for Multiple Types of Cancer (PR Newswire)
Sep-10-24 06:59AM	Q1 2025 Avid Bioservices Inc Earnings Call (Thomson Reuters StreetEvents)
Sep-05-24 11:31AM	Halozyme Therapeutics (HALO) Up 14.8% Since Last Earnings Report: Can It Continue? (Zacks)
Sep-02-24 09:50AM	Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term (Zacks)
Aug-28-24 08:30AM	Halozyme to Present at Upcoming Investor Conferences (PR Newswire)
Aug-27-24 09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Aug-23-24 03:03PM	Halozyme Earnings, Guidance Point to Bullish Future (FX Empire)
Aug-14-24 07:01PM	Insider Sale: Director Matthew Posard Sells 29,881 Shares of Halozyme Therapeutics Inc (HALO) (GuruFocus.com)
Aug-12-24 04:37PM	Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates (PR Newswire)
Aug-07-24 04:11PM	How These Two Lesser-Known Biotech Names Obliterated Sales Expectations (Investor's Business Daily)
10:39AM	Halozyme's (HALO) Q2 Earnings & Sales Top Estimates, Stock Up (Zacks)
Aug-06-24 06:30PM	Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics (Zacks)
05:50PM	Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Beat Estimates (Zacks)
04:45PM	Halozyme Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:19PM	Halozyme And Ligand Two Leading Biotechs Smash Quarterly Forecasts (Investor's Business Daily)
04:01PM	HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS (PR Newswire)
Aug-05-24 09:16AM	Curious about Halozyme Therapeutics (HALO) Q2 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
Aug-04-24 01:33PM	3 Biotech Stocks on Track for 50% Returns (or More) by 2028 (InvestorPlace)
Jul-26-24 09:45AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock (Zacks)
Jul-23-24 09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)
08:30AM	Halozyme to Report Second Quarter 2024 Financial and Operating Results (PR Newswire)
Jul-18-24 07:00AM	3 Biotech Stocks That Could Be Multibaggers in the Making: July Edition (InvestorPlace)
Jul-16-24 05:11PM	Big Money Eyes Halozyme for Strong Growth (FX Empire)
Jul-15-24 09:04PM	3 Biotech Stocks to Buy Now: Q3 Edition (InvestorPlace)
Jul-09-24 12:45PM	Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think 'Yes' (Zacks)
Jul-08-24 12:42PM	Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term (Zacks)
Jul-05-24 06:20AM	3 Highly Rated Biotech Stocks for Your July Buy List (InvestorPlace)
Jul-03-24 08:00AM	How Small Biotech Halozyme, With A 41% Run, Is Getting Under Your Skin (Investor's Business Daily)
Jul-01-24 10:02AM	3 Breakout Biotech Stocks on Track to Double by 2032 (InvestorPlace)
Jun-25-24 01:15AM	Halozyme Announces Roche's OCREVUS SC with ENHANZE Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis (PR Newswire)
Jun-21-24 05:15PM	Halozyme Announces argenx Receives FDA Approval for VYVGART Hytrulo Co-Formulated with ENHANZE for Chronic Inflammatory Demyelinating Polyneuropathy (PR Newswire)
Jun-17-24 09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Jun-15-24 04:00PM	The 3 Best Healthcare Stocks to Buy in June 2024 (InvestorPlace)
Jun-13-24 07:00PM	Insider Sale: Director Matthew Posard Sells Shares of Halozyme Therapeutics Inc (HALO) (GuruFocus.com)
Jun-11-24 01:13PM	Halozyme Therapeutics, Inc. (NASDAQ:HALO) Downgraded by Piper Sandler (Insider Monkey)
09:50AM	Halozyme Therapeutics (HALO) is a Top-Ranked Momentum Stock: Should You Buy? (Zacks)
09:06AM	Analysts on Wall Street Lower Ratings for These 10 Stocks (Insider Monkey)
Jun-07-24 01:52PM	Halozyme Therapeutics Scores RS Rating Jump To 91 (Investor's Business Daily)
08:59AM	Halozyme (HALO) Raises 2024 Financial Guidance, Stock Up 13% (Zacks)
Jun-06-24 11:31AM	Halozyme Therapeutics (HALO) Up 8.7% Since Last Earnings Report: Can It Continue? (Zacks) +12.68%
09:31AM	Halozyme's (HALO) ENHANZE Product Gets New Patent Grant in EU (Zacks)
08:30AM	Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook (PR Newswire)
Jun-05-24 04:05PM	Halozyme Announces Issuance of New European Patent for ENHANZE Drug Delivery Platform (PR Newswire)
Jun-04-24 04:30PM	Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference (PR Newswire)
May-31-24 09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)
May-21-24 07:15AM	Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE (PR Newswire)
May-20-24 09:50AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock (Zacks)

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Henderson Jeffrey William	Director	Jan 06 '25	Sale	50.01	10,000	500,060	43,611	Jan 07 04:14 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Jan 03 '25	Option Exercise	0.00	7,611	0	19,291	Jan 06 05:12 PM
JEFFREY HENDERSON	Director	Jan 06 '25	Proposed Sale	47.74	10,000	477,400		Jan 06 04:26 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Oct 16 '24	Option Exercise	19.98	10,000	199,800	183,756	Oct 16 06:53 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Oct 15 '24	Option Exercise	18.15	10,000	181,455	183,756	Oct 16 06:53 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Oct 15 '24	Sale	53.75	10,000	537,469	173,756	Oct 16 06:53 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Oct 16 '24	Sale	53.26	10,000	532,590	173,756	Oct 16 06:53 PM
MICHAEL LABARRE	Officer	Oct 16 '24	Proposed Sale	53.26	10,000	532,592		Oct 16 04:14 PM
MICHAEL LABARRE	Officer	Oct 15 '24	Proposed Sale	53.75	10,000	537,466		Oct 15 04:34 PM
Torley Helen	PRESIDENT AND CEO	Oct 08 '24	Option Exercise	13.87	10,000	138,700	686,744	Oct 09 05:39 PM
Torley Helen	PRESIDENT AND CEO	Oct 09 '24	Option Exercise	13.87	10,000	138,700	686,744	Oct 09 05:39 PM
Torley Helen	PRESIDENT AND CEO	Oct 08 '24	Sale	54.00	10,000	539,961	676,744	Oct 09 05:39 PM
Torley Helen	PRESIDENT AND CEO	Oct 09 '24	Sale	52.58	10,000	525,783	676,744	Oct 09 05:39 PM
HELEN TORLEY	Officer	Oct 09 '24	Proposed Sale	52.58	10,000	525,778		Oct 09 04:09 PM
HELEN TORLEY	Officer	Oct 08 '24	Proposed Sale	54.00	10,000	539,956		Oct 08 04:08 PM
Torley Helen	PRESIDENT AND CEO	Sep 26 '24	Option Exercise	13.87	10,000	138,700	686,744	Sep 26 06:06 PM
Torley Helen	PRESIDENT AND CEO	Sep 24 '24	Option Exercise	13.87	10,000	138,700	686,744	Sep 26 06:06 PM
Torley Helen	PRESIDENT AND CEO	Sep 25 '24	Option Exercise	13.87	10,000	138,700	686,744	Sep 26 06:06 PM
Torley Helen	PRESIDENT AND CEO	Sep 24 '24	Sale	58.21	10,000	582,100	676,744	Sep 26 06:06 PM
Torley Helen	PRESIDENT AND CEO	Sep 25 '24	Sale	56.34	10,000	563,370	676,744	Sep 26 06:06 PM
Torley Helen	PRESIDENT AND CEO	Sep 26 '24	Sale	56.10	10,000	560,970	676,744	Sep 26 06:06 PM
HELEN TORLEY	Officer	Sep 26 '24	Proposed Sale	56.10	10,000	560,970		Sep 26 04:05 PM
HELEN TORLEY	Officer	Sep 25 '24	Proposed Sale	56.34	10,000	563,368		Sep 25 04:00 PM
HELEN TORLEY	Officer	Sep 24 '24	Proposed Sale	58.21	10,000	582,101		Sep 24 04:05 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sep 17 '24	Option Exercise	16.65	10,000	166,500	183,756	Sep 18 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sep 18 '24	Option Exercise	16.65	10,000	166,500	183,756	Sep 18 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sep 17 '24	Sale	62.88	10,000	628,780	173,756	Sep 18 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sep 18 '24	Sale	62.03	10,000	620,316	173,756	Sep 18 06:49 PM
MICHAEL LABARRE	Officer	Sep 18 '24	Proposed Sale	62.03	10,000	620,311		Sep 18 04:01 PM
MICHAEL LABARRE	Officer	Sep 17 '24	Proposed Sale	62.88	10,000	628,777		Sep 17 04:03 PM
Torley Helen	PRESIDENT AND CEO	Sep 10 '24	Option Exercise	13.87	10,000	138,700	686,744	Sep 12 05:56 PM
Torley Helen	PRESIDENT AND CEO	Sep 12 '24	Option Exercise	13.87	10,000	138,700	686,744	Sep 12 05:56 PM
Torley Helen	PRESIDENT AND CEO	Sep 11 '24	Option Exercise	13.87	10,000	138,700	686,744	Sep 12 05:56 PM
Torley Helen	PRESIDENT AND CEO	Sep 12 '24	Sale	59.20	10,000	592,030	676,744	Sep 12 05:56 PM
Torley Helen	PRESIDENT AND CEO	Sep 10 '24	Sale	59.09	10,000	590,890	676,744	Sep 12 05:56 PM
Torley Helen	PRESIDENT AND CEO	Sep 11 '24	Sale	59.09	10,000	590,870	676,744	Sep 12 05:56 PM
HELEN TORLEY	Officer	Sep 12 '24	Proposed Sale	59.20	10,000	592,028		Sep 12 04:12 PM
HELEN TORLEY	Officer	Sep 11 '24	Proposed Sale	59.09	10,000	590,873		Sep 11 04:05 PM
HELEN TORLEY	Officer	Sep 10 '24	Proposed Sale	59.09	10,000	590,897		Sep 10 04:16 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Aug 27 '24	Option Exercise	18.41	5,580	102,728	173,756	Aug 27 07:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Aug 20 '24	Option Exercise	16.65	10,000	166,500	178,176	Aug 21 06:03 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Aug 21 '24	Option Exercise	16.65	10,000	166,500	178,176	Aug 21 06:03 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Aug 21 '24	Sale	61.75	10,000	617,470	168,176	Aug 21 06:03 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Aug 20 '24	Sale	61.05	10,000	610,550	168,176	Aug 21 06:03 PM
MICHAEL LABARRE	Officer	Aug 21 '24	Proposed Sale	61.75	10,000	617,474		Aug 21 04:11 PM
MICHAEL LABARRE	Officer	Aug 20 '24	Proposed Sale	61.06	10,000	610,553		Aug 20 04:16 PM
Torley Helen	PRESIDENT AND CEO	Aug 13 '24	Option Exercise	13.87	10,000	138,700	686,744	Aug 15 04:59 PM
Torley Helen	PRESIDENT AND CEO	Aug 14 '24	Option Exercise	13.87	10,000	138,700	686,744	Aug 15 04:59 PM
Torley Helen	PRESIDENT AND CEO	Aug 15 '24	Option Exercise	13.87	10,000	138,700	686,744	Aug 15 04:59 PM
Torley Helen	PRESIDENT AND CEO	Aug 15 '24	Sale	57.95	10,000	579,490	676,744	Aug 15 04:59 PM
Torley Helen	PRESIDENT AND CEO	Aug 14 '24	Sale	57.25	10,000	572,471	676,744	Aug 15 04:59 PM
Torley Helen	PRESIDENT AND CEO	Aug 13 '24	Sale	56.25	10,000	562,490	676,744	Aug 15 04:59 PM
HELEN TORLEY	Officer	Aug 15 '24	Proposed Sale	57.95	10,000	579,488		Aug 15 04:31 PM
Posard Matthew L.	Director	Aug 14 '24	Sale	57.70	9,881	570,134	69,874	Aug 14 04:57 PM
Posard Matthew L.	Director	Aug 13 '24	Sale	56.19	10,000	561,930	79,755	Aug 14 04:57 PM
Posard Matthew L.	Director	Aug 12 '24	Sale	55.72	10,000	557,230	89,755	Aug 14 04:57 PM
HELEN TORLEY	Officer	Aug 14 '24	Proposed Sale	57.25	10,000	572,472		Aug 14 04:08 PM
HELEN TORLEY	Officer	Aug 13 '24	Proposed Sale	56.25	10,000	562,496		Aug 13 04:19 PM
Posard Matthew L.	affiliate	Aug 13 '24	Proposed Sale	54.15	30,000	1,624,500		Aug 07 04:41 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jul 24 '24	Option Exercise	15.19	10,000	151,854	178,176	Jul 24 05:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jul 23 '24	Option Exercise	8.11	10,000	81,100	178,176	Jul 24 05:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jul 24 '24	Sale	55.12	10,000	551,150	168,176	Jul 24 05:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jul 23 '24	Sale	54.89	10,000	548,873	168,176	Jul 24 05:48 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jul 22 '24	Option Exercise	22.50	5,000	112,500	19,488	Jul 23 04:37 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jul 22 '24	Sale	53.93	5,000	269,662	15,480	Jul 23 04:37 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jun 26 '24	Option Exercise	22.50	10,000	225,000	25,480	Jun 28 04:06 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jun 27 '24	Option Exercise	22.50	10,000	225,000	25,480	Jun 28 04:06 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jun 28 '24	Option Exercise	22.50	10,000	225,000	25,480	Jun 28 04:06 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jun 28 '24	Sale	52.04	10,000	520,400	15,480	Jun 28 04:06 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jun 27 '24	Sale	51.93	10,000	519,340	15,480	Jun 28 04:06 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jun 26 '24	Sale	51.82	10,000	518,200	15,480	Jun 28 04:06 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jun 18 '24	Option Exercise	8.11	10,000	81,100	178,176	Jun 20 04:17 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jun 18 '24	Sale	49.43	10,000	494,260	168,176	Jun 20 04:17 PM
Posard Matthew L.	Director	Jun 12 '24	Sale	50.62	10,000	506,190	99,755	Jun 13 04:15 PM
Posard Matthew L.	Director	Jun 11 '24	Sale	50.01	10,000	500,110	109,755	Jun 13 04:15 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	May 22 '24	Option Exercise	8.11	10,000	81,100	178,176	May 22 05:24 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	May 21 '24	Option Exercise	8.11	10,000	81,100	178,176	May 22 05:24 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	May 22 '24	Sale	45.38	10,000	453,840	168,176	May 22 05:24 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	May 21 '24	Sale	45.16	10,000	451,640	168,176	May 22 05:24 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Apr 16 '24	Option Exercise	8.11	10,000	81,100	178,176	Apr 17 07:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Apr 17 '24	Option Exercise	8.11	10,000	81,100	178,176	Apr 17 07:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Apr 17 '24	Sale	38.49	10,000	384,890	168,176	Apr 17 07:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Apr 16 '24	Sale	38.35	10,000	383,500	168,176	Apr 17 07:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Mar 26 '24	Option Exercise	11.20	11,618	130,160	168,176	Mar 26 07:38 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Mar 12 '24	Option Exercise	12.07	10,000	120,700	166,558	Mar 13 05:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Mar 13 '24	Option Exercise	10.66	10,000	106,638	166,558	Mar 13 05:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Mar 13 '24	Sale	42.27	10,000	422,730	156,558	Mar 13 05:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Mar 12 '24	Sale	41.64	10,000	416,370	156,558	Mar 13 05:22 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 28 '24	Option Exercise	8.11	7,471	60,590	164,029	Feb 28 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 27 '24	Sale	39.95	10,000	399,460	159,087	Feb 28 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 28 '24	Sale	39.55	10,000	395,463	156,558	Feb 28 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 16 '24	Option Exercise	0.00	10,376	0	171,247	Feb 20 06:59 PM
Snyder Mark Howard	SVP, GENERAL COUNSEL	Feb 16 '24	Option Exercise	0.00	4,796	0	14,257	Feb 20 06:55 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 16 '24	Option Exercise	0.00	10,422	0	18,344	Feb 20 06:53 PM
Torley Helen	PRESIDENT AND CEO	Feb 16 '24	Option Exercise	0.00	37,884	0	685,814	Feb 20 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 15 '24	Option Exercise	0.00	3,386	0	160,529	Feb 16 05:47 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 15 '24	Option Exercise	0.00	1,254	0	11,345	Feb 16 05:41 PM
Torley Helen	PRESIDENT AND CEO	Feb 15 '24	Option Exercise	0.00	13,092	0	651,096	Feb 16 05:39 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 10 '24	Option Exercise	0.00	8,133	0	160,044	Feb 13 04:18 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 10 '24	Option Exercise	0.00	2,502	0	11,568	Feb 13 04:15 PM

Open in Screener

FGEN

FibroGen Inc

Jan 17 • 04:00PM ET

0.5728

Dollar change -0.0066
Percentage change -1.14	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BMRN REGN ALNY IONS NBIX MDGL EXEL ARGX PRTA

| Held by: VTI VXF FESM VHT IWC BTEC

Index	-	P/E	-	EPS (ttm)	-1.23	Insider Own	7.02%	Shs Outstand	100.77M	Perf Week	-7.01%
Market Cap	57.72M	Forward P/E	-	EPS next Y	-0.46	Insider Trans	0.00%	Shs Float	93.69M	Perf Month	76.19%
Income	-121.79M	PEG	-	EPS next Q	-0.14	Inst Own	45.46%	Short Float	3.26%	Perf Quarter	52.46%
Sales	180.01M	P/S	0.32	EPS this Y	72.60%	Inst Trans	-21.83%	Short Ratio	2.13	Perf Half Y	-44.92%
Book/sh	-2.42	P/B	-	EPS next Y	43.12%	ROA	-33.61%	Short Interest	3.05M	Perf Year	-23.63%
Cash/sh	1.30	P/C	0.44	EPS next 5Y	-	ROE	-	52W Range	0.18 - 2.93	Perf YTD	8.18%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-23.23%	ROI	-	52W High	-80.45%	Beta	0.76
Dividend TTM	-	Quick Ratio	1.16	Sales past 5Y	-8.26%	Gross Margin	76.87%	52W Low	218.22%	ATR (14)	0.08
Dividend Ex-Date	-	Current Ratio	1.28	EPS Y/Y TTM	59.81%	Oper. Margin	-52.44%	RSI (14)	57.38	Volatility	15.50% 16.61%
Employees	486	Debt/Eq	-	Sales Y/Y TTM	16.15%	Profit Margin	-67.66%	Recom	2.00	Target Price	10.00
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	73.75%	Payout	-	Rel Volume	0.89	Prev Close	0.58
Sales Surprise	32.98%	EPS Surprise	44.50%	Sales Q/Q	15.45%	Earnings	Nov 12 AMC	Avg Volume	1.43M	Price	0.57
SMA20	5.85%	SMA50	32.22%	SMA200	-19.48%	Trades		Volume	1,270,924	Change	-1.14%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-08-23	Downgrade	BofA Securities	Neutral → Underperform	$4 → $2
Jun-26-23	Downgrade	William Blair	Outperform → Mkt Perform
Jun-26-23	Downgrade	Stifel	Buy → Hold
Jun-26-23	Downgrade	Raymond James	Outperform → Mkt Perform
Jun-26-23	Downgrade	BofA Securities	Buy → Neutral
Jun-02-23	Upgrade	Stifel	Hold → Buy	$23 → $32
Jan-31-23	Upgrade	William Blair	Mkt Perform → Outperform
Jan-26-23	Upgrade	Raymond James	Mkt Perform → Outperform	$35
Jan-05-23	Upgrade	BofA Securities	Neutral → Buy	$18 → $27
Sep-22-21	Downgrade	Goldman	Neutral → Sell	$16 → $11
Aug-20-21	Upgrade	Raymond James	Underperform → Mkt Perform
Jul-16-21	Downgrade	Stifel	Buy → Hold	$55 → $29
Jul-16-21	Downgrade	BofA Securities	Buy → Neutral	$29
Apr-07-21	Downgrade	Mizuho	Buy → Neutral	$72 → $29
Apr-07-21	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-31-21	Upgrade	BofA Securities	Neutral → Buy	$47
Mar-02-21	Downgrade	Jefferies	Buy → Hold	$75 → $45
Feb-01-21	Initiated	H.C. Wainwright	Buy	$58
Oct-26-20	Initiated	Raymond James	Underperform
Jul-10-20	Resumed	Stifel	Buy	$71

Show Previous Ratings

Dec-16-24 08:05AM	FibroGen Appoints David DeLucia as Chief Financial Officer (GlobeNewswire)
Nov-13-24 10:22AM	Q3 2024 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents) -14.07%
02:21AM	FibroGen Inc (FGEN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Cost Reductions (GuruFocus.com)
Nov-12-24 06:10PM	FibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +14.18%
05:06PM	FibroGen: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	FibroGen Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-04-24 04:05PM	FibroGen to Report Third Quarter 2024 Financial Results (GlobeNewswire) -5.65%
Oct-09-24 05:09PM	FibroGen Inc (FGEN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Shifts (GuruFocus.com)
Sep-16-24 01:32AM	Duchenne muscular dystrophy: major trials and events to watch in 2023 (Clinical Trials Arena)
Sep-03-24 04:05PM	FibroGen to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -9.19% +20.36%
Aug-06-24 06:15PM	FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
05:10PM	FibroGen: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	FibroGen Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-24 11:54AM	FibroGen axes 75% of staff after lead cancer therapy fails in Phase III trials (Pharmaceutical Technology) -47.56%
07:33AM	Vertexs pain drug gets speedy FDA review; Keytruda hits a sales milestone (BioPharma Dive)
04:07PM	Loading…
Jul-30-24 04:07PM	FibroGen to Report Second Quarter 2024 Financial Results (GlobeNewswire) -8.04%
04:05PM	FibroGen Announces Topline Results from Two Late-Stage Pamrevlumab Pancreatic Cancer Studies and Provides Corporate Update (GlobeNewswire)
Jun-18-24 08:00AM	FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer on June 26, 2024 (GlobeNewswire)
Jun-12-24 10:22AM	Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments (PR Newswire)
Jun-04-24 07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
Jun-03-24 04:05PM	FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO in Upcoming Clinical Trials (GlobeNewswire)
04:02PM	FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors (GlobeNewswire)
09:17AM	Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates (PR Newswire)
07:00AM	FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-28-24 06:10AM	7 Penny Biotech Stocks to Triple Your Investment (InvestorPlace)
May-23-24 05:05PM	FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
May-07-24 10:15AM	FibroGen, Inc. (NASDAQ:FGEN) Q1 2024 Earnings Call Transcript (Insider Monkey) +18.10%
08:57AM	Q1 2024 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents)
07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:36AM	Top Premarket Gainers (MT Newswires)
07:00AM	Loading…
07:00AM	FibroGen to Participate in Upcoming Investor Conferences (GlobeNewswire)
03:14AM	FibroGen Inc (FGEN) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-06-24 08:58PM	FGEN Stock Earnings: FibroGen Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:25PM	FibroGen: Q1 Earnings Snapshot (Associated Press Finance)
04:02PM	FibroGen Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-29-24 07:00AM	FibroGen to Report First Quarter 2024 Financial Results (GlobeNewswire)
Apr-24-24 04:02PM	FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) -8.01%
Apr-03-24 09:32AM	Prostate cancer ADC acquired from Fortis breaks FibroGen's clinical losing streak (FierceBiotech.com) -31.94%
Apr-02-24 05:46PM	FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer (GlobeNewswire) -8.47%
Mar-26-24 07:00AM	FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) -7.58%
Mar-20-24 03:45PM	3 Nightmare Nasdaq Stocks Not Worth Holding Another Day (InvestorPlace)
Mar-11-24 07:00AM	FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer (GlobeNewswire)
Feb-29-24 08:09AM	FibroGen, Inc. (NASDAQ:FGEN) Q4 2023 Earnings Call Transcript (Insider Monkey) -13.85%
Feb-27-24 09:59AM	Q4 2023 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents) +14.59%
Feb-26-24 05:50PM	FibroGen: Q4 Earnings Snapshot (Associated Press Finance)
04:40PM	FibroGen Inc (FGEN) Reports Modest Revenue Growth and Reduced Net Loss in FY 2023 (GuruFocus.com)
04:34PM	UPDATE 1-FibroGen regains rights to anemia drug from AstraZeneca (Reuters)
04:15PM	FibroGen regains rights to anemia drug from AstraZeneca (Reuters)
04:06PM	FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
04:05PM	FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea (GlobeNewswire)
Feb-20-24 07:00AM	FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) -17.81%
Feb-05-24 07:00AM	FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024 (GlobeNewswire) +8.87%
Jan-25-24 07:00AM	FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network's Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer (GlobeNewswire) +13.37%
Dec-09-23 05:02PM	FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting (GlobeNewswire)
Nov-07-23 11:01AM	FibroGen, Inc. (NASDAQ:FGEN) Q3 2023 Earnings Call Transcript (Insider Monkey)
10:01AM	Q3 2023 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-06-23 05:33PM	FibroGen Inc (FGEN) Reports 155% YoY Increase in Q3 2023 Net Revenue (GuruFocus.com) -13.62%
05:30PM	FibroGen (FGEN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
04:10PM	FibroGen: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	FibroGen Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-23-23 07:00AM	FibroGen to Report Third Quarter 2023 Financial Results (GlobeNewswire) -7.77%
Aug-31-23 10:15AM	Biotech Stock Roundup: FGEN Down on Study Failure, BMY Drug's Label Expansion & More (Zacks)
Aug-30-23 11:09AM	FibroGen (FGEN) Fails to Meet Goals in DMD Study, Stock Down 23% (Zacks) -24.23%
Aug-29-23 06:00PM	FibroGen's drug misses mark on yet another clinical trial (American City Business Journals)
04:15PM	FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy (GlobeNewswire)
Aug-16-23 09:35AM	Down -46.88% in 4 Weeks, Here's Why FibroGen (FGEN) Looks Ripe for a Turnaround (Zacks)
Aug-09-23 09:14AM	Is There An Opportunity With FibroGen, Inc.'s (NASDAQ:FGEN) 42% Undervaluation? (Simply Wall St.)
Aug-08-23 10:08AM	Q2 2023 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents) -18.64%
08:59AM	FibroGen, Inc. (NASDAQ:FGEN) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-07-23 07:30PM	FibroGen (FGEN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) -7.33%
05:40PM	FibroGen (FGEN) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:26PM	FibroGen: Q2 Earnings Snapshot (AP Finance)
04:01PM	FibroGen Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-31-23 09:00AM	FibroGen limits rare-disease drug's access after clinical trial failure. Some parents say it was saving their kids' lives (American City Business Journals) +7.29%
Jul-25-23 10:49AM	FibroGen CEO resigns after back-to-back drug study failures, job cuts (American City Business Journals) -5.74%
07:00AM	FibroGen Announces Leadership Transition (GlobeNewswire)
Jul-24-23 07:00AM	FibroGen to Report Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-21-23 07:17AM	Eliem (ELYM) to Explore Strategic Options, Stock Rises 6% (Zacks) -5.41%
Jul-19-23 10:50AM	Pioneering Mission Bay biotech company Fibrogen to cut more than 100 jobs (American City Business Journals) -7.03%
Jul-14-23 09:55AM	FibroGen (FGEN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
Jul-11-23 09:35AM	Down -83.78% in 4 Weeks, Here's Why FibroGen (FGEN) Looks Ripe for a Turnaround (Zacks)
Jul-01-23 08:46AM	Down 80% in 1 Day, Is There Any Hope for FibroGen Stock? (Motley Fool)
Jun-27-23 12:45PM	FibroGen (FGEN) Plunges on Failure of Late-Stage IPF Study (Zacks) -7.38%
Jun-26-23 04:04PM	FibroGen Crashes To Its Lowest-Ever Point On A Second Failure For Its Lead Drug (Investor's Business Daily) -83.12%
11:34AM	FibroGen, Inc.'s (NASDAQ:FGEN) institutional investors lost 4.0% last week but have benefitted from longer-term gains (Simply Wall St.)
07:22AM	UPDATE 2-FibroGen's drug fails late-stage trial for treating lung disease (Reuters)
07:11AM	FibroGen's lung disease treatment fails in late-stage trial (Reuters)
07:04AM	FibroGen Announces Topline Results from Phase 3 ZEPHYRUS-1 Study of Pamrevlumab for the Treatment of Idiopathic Pulmonary Fibrosis (GlobeNewswire)
Jun-08-23 01:03PM	FibroGen (FGEN) Pamrevlumab Fails DMD Study, Stock Down 8% (Zacks)
Jun-07-23 04:03PM	FibroGen Stock Plunges Under Key Lines As Lead Drug Fails; Why Hope Isn't Lost (Investor's Business Daily) -8.44%
11:47AM	FibroGen's One Study For Duchenne Muscular Dystrophy Fails To Hit Main Goal (Benzinga)
07:02AM	FibroGen's neuromuscular disease drug fails to meet main goal in late-stage study (Reuters)
06:55AM	FibroGen Announces Topline Results from LELANTOS-1 Phase 3 Clinical Study of Pamrevlumab in Non-Ambulatory Patients with Duchenne Muscular Dystrophy (GlobeNewswire)
Jun-06-23 04:01PM	FibroGen to Present at Jefferies Global Healthcare Conference (GlobeNewswire)
02:06PM	FibroGen Stock Joins Rank Of Stocks With RS Ratings Over 90 (Investor's Business Daily)
May-18-23 07:30AM	FibroGen Announces Positive Topline Results from China Pivotal Phase 3 Clinical Trial of Roxadustat for the Treatment of Chemotherapy Induced Anemia (GlobeNewswire)
May-09-23 10:22AM	Q1 2023 FibroGen Inc Earnings Call (Thomson Reuters StreetEvents)
May-08-23 05:15PM	FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:12PM	FibroGen: Q1 Earnings Snapshot (AP Finance)
04:01PM	FibroGen Reports First Quarter 2023 Financial Results (GlobeNewswire)

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Adib Deyaa	Chief Medical Officer	Jun 12 '24	Buy	1.17	22,123	25,884	82,123	Jun 13 04:30 PM
Wettig Thane	CEO	Mar 07 '24	Buy	1.91	50,000	95,470	470,178	Mar 11 07:06 PM

Open in Screener

QCOM

Qualcomm, Inc

Jan 17 • 04:00PM ET

164.56

Dollar change +3.13
Percentage change 1.94	%

Technology • Semiconductors • USA • NASD

Peers: INTC AVGO AMD NVDA NXPI SWKS TXN MCHP QRVO MRVL

| Held by: VTI VOO QQQ SPY IVV VTV XLK SMH VGT VIG

Index	NDX, S&P 500	P/E	18.33	EPS (ttm)	8.98	Insider Own	0.09%	Shs Outstand	1.11B	Perf Week	4.83%
Market Cap	182.83B	Forward P/E	13.40	EPS next Y	12.28	Insider Trans	-7.62%	Shs Float	1.11B	Perf Month	4.22%
Income	10.14B	PEG	3.86	EPS next Q	2.97	Inst Own	77.21%	Short Float	2.26%	Perf Quarter	-4.04%
Sales	38.96B	P/S	4.69	EPS this Y	9.92%	Inst Trans	-1.30%	Short Ratio	3.10	Perf Half Y	-14.05%
Book/sh	23.61	P/B	6.97	EPS next Y	9.30%	ROA	19.04%	Short Interest	25.06M	Perf Year	18.12%
Cash/sh	11.97	P/C	13.75	EPS next 5Y	4.75%	ROE	42.25%	52W Range	137.35 - 230.63	Perf YTD	7.12%
Dividend Est.	3.57 (2.17%)	P/FCF	16.38	EPS past 5Y	20.08%	ROI	25.20%	52W High	-28.65%	Beta	1.25
Dividend TTM	3.35 (2.04%)	Quick Ratio	1.72	Sales past 5Y	12.22%	Gross Margin	56.22%	52W Low	19.81%	ATR (14)	4.37
Dividend Ex-Date	Dec 05, 2024	Current Ratio	2.40	EPS Y/Y TTM	40.47%	Oper. Margin	26.31%	RSI (14)	58.98	Volatility	2.19% 2.48%
Employees	49000	Debt/Eq	0.59	Sales Y/Y TTM	8.77%	Profit Margin	26.03%	Recom	2.17	Target Price	200.32
Option/Short	Yes / Yes	LT Debt/Eq	0.53	EPS Q/Q	95.41%	Payout	36.77%	Rel Volume	0.98	Prev Close	161.43
Sales Surprise	3.43%	EPS Surprise	5.07%	Sales Q/Q	18.69%	Earnings	Nov 06 AMC	Avg Volume	8.08M	Price	164.56
SMA20	4.39%	SMA50	2.89%	SMA200	-6.21%	Trades		Volume	7,938,726	Change	1.94%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-17-25	Reiterated	Barclays	Overweight	$200 → $185
Dec-09-24	Initiated	Melius	Hold	$180
Nov-12-24	Initiated	Loop Capital	Hold	$180
Oct-16-24	Reiterated	Citigroup	Neutral	$200 → $185
Oct-08-24	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Aug-12-24	Downgrade	Wolfe Research	Outperform → Peer Perform
Aug-02-24	Upgrade	DZ Bank	Hold → Buy	$210
Jul-17-24	Downgrade	HSBC Securities	Buy → Hold	$200
Jun-04-24	Reiterated	TD Cowen	Buy	$200 → $235
May-31-24	Reiterated	BofA Securities	Buy	$180 → $245
Apr-23-24	Initiated	The Benchmark Company	Buy	$200
Apr-16-24	Initiated	Evercore ISI	In-line	$177
Feb-01-24	Reiterated	TD Cowen	Outperform	$160 → $170
Feb-01-24	Downgrade	Citigroup	Buy → Neutral	$160
Jan-23-24	Initiated	Cantor Fitzgerald	Neutral	$150
Jan-12-24	Upgrade	Citigroup	Neutral → Buy	$160
Dec-08-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$119 → $132
Aug-09-23	Downgrade	Daiwa Securities	Buy → Outperform	$125
Aug-03-23	Downgrade	Deutsche Bank	Buy → Hold	$130 → $121
Jul-25-23	Reiterated	Susquehanna	Positive	$135 → $145

Show Previous Ratings

Jan-17-25 09:00PM	How a Little-Known Finnish Company Became One of the Worlds Hottest Gadget Startups (The Wall Street Journal)
12:53PM	Intel's Stock Skyrockets 9%--Is a Major Acquisition on the Horizon? (GuruFocus.com)
09:41AM	Why Intel (INTC) Stock Is Rallying Today (Insider Monkey)
09:06AM	Is QUALCOMM Incorporated (QCOM) the Best NASDAQ Dividend Stock to Buy? (Insider Monkey)
09:00AM	Qualcomm Announces Quarterly Cash Dividend (Business Wire)
05:15AM	Loading…
05:15AM	Prediction: These 3 Artificial Intelligence (AI) Chip Stocks Will Crush the Market in 2025 (Motley Fool)
Jan-16-25 12:26PM	QUALCOMM Incorporated (QCOM): Advancing AI-Powered Snapdragon Platforms to Seize a $900 Billion Opportunity (Insider Monkey)
05:15AM	Qualcomm Is Going After Intel and AMD in This Lucrative Market (Motley Fool)
03:41AM	Why QUALCOMM Incorporated (QCOM) Is Among the Top Undervalued Tech Stocks to Buy According to Hedge Funds? (Insider Monkey)
Jan-14-25 05:45PM	Qualcomm (QCOM) Rises Higher Than Market: Key Facts (Zacks)
02:04PM	Qualcomms Latest Hire Suggests New Interest in Data-Center Chips. It Could Come at Intels Expense. (Barrons.com)
10:34AM	US restrictions on AI chips are a 'step in the wrong direction' (Yahoo Finance Video)
01:30AM	Tech Stocks Are Expensive. Micron and 2 Others That Look Cheapand Have Momentum. (Barrons.com)
Jan-13-25 11:51AM	Nvidia stock falls after Biden administration releases updated export rule for AI chips (Yahoo Finance)
11:38AM	Is QUALCOMM Incorporated (QCOM) the Most Reliable Dividend Stock to Buy According to Hedge Funds? (Insider Monkey)
08:03AM	Loading…
08:03AM	Exclusive-Tech supplier Arm plans to hike prices, has considered developing its own chips (Reuters)
04:36AM	Desay SV, Qualcomm to launch new AI cabin platform for automotive OEMs (Just Auto)
Jan-12-25 09:29PM	Qualcomm and NXP drive AI integration in consumer and automotive electronics at CES 2025 (DigiTimes)
04:55AM	2 Top Bargain Stocks Ready for a Bull Run (Motley Fool)
Jan-11-25 05:00AM	AI-powered PCs, agents and assistants, and wearables: This week's AI launches (Quartz)
Jan-10-25 05:39PM	Garmin (GRMN) and Qualcomm Launch Unified Cabin 2025: AI-Powered Digital Cockpit for Vehicles (Insider Monkey)
11:39AM	Why Nvidia (NVDA), AMD (AMD) Are Pulling Back Today (Insider Monkey)
10:32AM	Qualcomm CEO hints at future high-powered PC chips (Yahoo Finance)
10:32AM	Qualcomm CEO Amon hints at future graphics products for PCs, taking aim at Nvidia (Yahoo Finance)
08:39AM	Nvidia stock sell-off: Time to back up the truck? (Yahoo Finance)
Jan-09-25 09:28PM	Tata Elxsi and Qualcomm join forces to create virtual models of Snapdragon Digital Chassis solutions at CES 2025 (DigiTimes)
10:25AM	The 3 biggest takeaways from CES 2025 (Yahoo Finance)
06:20AM	Qualcomm's Budget PC Chips Don't Solve Its Biggest Problem (Motley Fool)
01:59AM	CES 2025 highlights rising interest in autonomous vehicles, Nvidia and Qualcomm lead in ecosystem competition (DigiTimes)
Jan-08-25 05:45PM	Qualcomm (QCOM) Stock Slides as Market Rises: Facts to Know Before You Trade (Zacks)
12:08PM	Loading…
12:08PM	QUALCOMM Incorporated (QCOM) Launches Snapdragon X Platform, Delivering AI-Powered Performance for Budget-Friendly Copilot+ PCs (Insider Monkey)
Jan-07-25 07:55PM	Major mobile SoC designers unlikely to adopt 2nm technology by 2025 (DigiTimes)
07:45PM	Qualcomm CEO: We're just getting started on our PC push (Yahoo Finance Video)
03:29PM	Amazon integrates Alexa into BMW cars; teams with Qualcomm for auto AI (Chain Store Age)
03:25PM	The AI Rollouts at CES Are Coming Fast. It Isnt Just Nvidia. (Barrons.com)
09:45AM	Here's Why Qualcomm (QCOM) is a Strong Growth Stock (Zacks)
09:00AM	QUALCOMM Incorporated (QCOM) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
06:29AM	Trimble, Qualcomm partner on positioning tech for autonomous vehicles (Just Auto)
Jan-06-25 09:56PM	Qualcomm's new chips will bring AI to US$600 personal computers (DigiTimes)
11:00AM	Qualcomm reveals Snapdragon X chip for AI PCs, new desktop system at CES 2025 (Yahoo Finance)
11:00AM	Qualcomm brings its Snapdragon X chips to mid-range Windows laptops and desktops (TechCrunch)
11:00AM	Qualcomms New Chips Will Bring AI to $600 Personal Computers (Bloomberg)
09:50AM	Nvidia, AMD, other chipmakers gain on Foxconn sales growth (Yahoo Finance Video)
09:24AM	What to expect from CES 2025: Techs biggest show goes all in on AI (Yahoo Finance)
09:00AM	Intel shows off AI PC chips at CES 2025 as AMD, Qualcomm pour on the pressure (Yahoo Finance)
09:00AM	Intel Says New Laptop Chips Will Extend Computer Battery Life (Bloomberg)
Jan-05-25 08:30AM	3 problems for the stock price of Nvidia rival AMD (Yahoo Finance)
Jan-03-25 09:00PM	Intels Problems Are Even Worse Than Youve Heard (The Wall Street Journal)
12:02PM	Tata Elxsi and Qualcomm partner to accelerate software-defined vehicle development (Just Auto)
12:00PM	Qualcomm (QCOM) Upgraded to Buy: Here's What You Should Know (Zacks)
Jan-02-25 05:45PM	Qualcomm (QCOM) Flat As Market Sinks: What You Should Know (Zacks)
08:16AM	Why Nvidia shouldnt sweat AI chip rivals like Amazon and Broadcom (Yahoo Finance)
05:06AM	LGES launches advanced EV battery management system (Just Auto)
Jan-01-25 09:40AM	Why Qualcomm (QCOM) is a Top Value Stock for the Long-Term (Zacks)
Dec-31-24 12:02AM	Beijing Pushes to Use China-Made Chips in Its EVs (The Wall Street Journal)
Dec-29-24 06:45PM	3 No-Brainer Artificial Intelligence (AI) Stocks to Buy for 2025 With $200 Right Now (Motley Fool)
Dec-28-24 08:17AM	QUALCOMM Incorporated (QCOM) Launches AI Program for Innovators 2025 to Support On-Device AI Solutions in Asia-Pacific (Insider Monkey)
04:50AM	2 Top Artificial Intelligence Stocks to Buy in January (Motley Fool)
Dec-26-24 07:56PM	From AI PCs to servers: Qualcomm, AMD challenge Intel's market dominance (DigiTimes)
05:45PM	Qualcomm (QCOM) Registers a Bigger Fall Than the Market: Important Facts to Note (Zacks)
09:50AM	Here's Why Qualcomm (QCOM) is a Strong Momentum Stock (Zacks)
04:57AM	What Does JPMorgans Upgrade Mean for Qualcomm (QCOM) Amid Ongoing Legal Battles? (Insider Monkey)
Dec-25-24 07:59PM	Samsung's overreliance on Qualcomm raises concerns (DigiTimes)
07:59PM	Qualcomm bets on automotive, IoT for ambitious growth (DigiTimes)
09:55AM	Wall Street Analysts Think Qualcomm (QCOM) Could Surge 28.45%: Read This Before Placing a Bet (Zacks)
Dec-24-24 08:10PM	Qualcomm's partial legal win brings industry relief, shifts focus to Arm's next moves (DigiTimes)
08:03PM	Analysts parse Qualcomm after Arm court ruling (TheStreet)
04:21PM	QUALCOMM Incorporated (QCOM) Wins Key Legal Battle Over Nuvia Technology Licensing (Insider Monkey)
10:15AM	Deutsche Bank views partial decision on Arm, Qualcomm dispute as incremental (TipRanks)
06:00AM	Nvidia dominated 2024 big-time. Next year? Plenty of challenges. (Yahoo Finance)
Dec-23-24 04:42PM	S&P 500 Gains and Losses Today: Chip Stocks Surge as Holiday Trading Week Begins (Investopedia)
04:28PM	These Stocks Moved the Most Today: Honda, Qualcomm, Broadcom, Lilly, ResMed, Tesla, Walmart, Rumble, and More (Barrons.com)
04:23PM	Arm, Qualcomm Shares Diverge After Lawsuit Verdict (Investor's Business Daily)
04:19PM	Broadcom, AMD Lead Chip Stocks Higher Monday on Anticipation of AI-Driven Gains (Investopedia)
02:45PM	These Stocks Are Moving the Most Today: Honda, Qualcomm, Broadcom, Lilly, ResMed, Tesla, Walmart, Rumble, and More (Barrons.com)
12:24PM	Jury Ruling Boosts Qualcomm, Weakens Arm in High-Stakes Licensing Battle (GuruFocus.com)
12:10PM	Eli Lilly, Qualcomm, Rumble: Market Minute (Yahoo Finance Video)
11:57AM	Why Arm Stock Is Sinking Today (Motley Fool)
10:37AM	Qualcomm's Legal Victory Over Arm Could Save $1.4 Billion in Annual Royalties (GuruFocus.com)
09:32AM	How To Earn $500 A Month From Qualcomm Stock (Benzinga)
09:07AM	Nvidia stock is in a 'soul-searching' moment (Yahoo Finance)
09:00AM	Investors Heavily Search QUALCOMM Incorporated (QCOM): Here is What You Need to Know (Zacks)
04:39AM	Qualcomm wins key legal battle against Arm, shares rise (Investing.com)
Dec-21-24 11:21PM	Is QUALCOMM Incorporated (QCOM) the Best Dividend Stock for Steady Income? (Insider Monkey)
09:22AM	Chip designer Arm will seek a retrial with Qualcomm as the Judge pushed for a verdict after the jury claimed they were at an Impasse (Patently Apple)
Dec-20-24 06:59PM	Qualcomm Prevails on Key Issues in Arm Suit (The Wall Street Journal)
06:46PM	Qualcomm Defeats Arms Claim Over Chip Design License Breach (Bloomberg)
06:34PM	Qualcomm Scores a Victory in Its Dispute With Longtime Partner Arm (Barrons.com)
05:01PM	Qualcomm scores major legal victory against Arm over chip designs (Investing.com)
04:52PM	Qualcomm not in breach of Nuvia-Arm licensing deal, jury finds (Yahoo Finance Video)
02:31PM	Qualcomm secures key win in chips trial against Arm (Reuters)
02:31PM	Arm lawsuit ends in mistrial with Qualcomm securing key win (Reuters)
11:01AM	QUALCOMM Incorporated (QCOM) Projects $1.4 Billion Savings in Arm Royalties Through Nuvia Acquisition (Insider Monkey)
Dec-19-24 05:45PM	Qualcomm (QCOM) Suffers a Larger Drop Than the General Market: Key Insights (Zacks)
07:07AM	Jury deliberates in Arm, Qualcomm trial after closing arguments wrap (Reuters)
Dec-18-24 06:22PM	Qualcomm saw Nuvia buy as chance to save $1.4 billion a year on Arm fees, CEO tells jury (Reuters)
09:40AM	Arm vs Qualcomm: The $1.4B Chip Design Battle That Could Reshape Tech (GuruFocus.com)
08:30AM	Technical Innovation Is at Heart of Global Explosion of Smart Glasses Markets as Demand Jumps (GlobeNewswire)
07:56AM	QUALCOMM (QCOM) Faces Arm in Court Over $1.4 Billion Nuvia Acquisition (Insider Monkey)
06:00AM	Nvidia's Blackwell chip could push the company into a new stratosphere as the AI revolution continues (Yahoo Finance)

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Palkhiwala Akash J.	CFO & COO	Jan 02 '25	Sale	154.62	3,000	463,851	66,021	Jan 03 04:38 PM
Akash Palkhiwala	Chief Financial Officer	Jan 02 '25	Proposed Sale	153.64	3,000	460,920		Jan 02 04:45 PM
ACE HEATHER S	Chief Human Resources Officer	Dec 15 '24	Option Exercise	0.00	8,037	0	16,702	Dec 16 05:41 PM
AMON CRISTIANO R	President & CEO	Dec 15 '24	Option Exercise	0.00	43,445	0	317,396	Dec 16 05:40 PM
CHAPLIN ANN C	General Counsel&Corp Secretary	Dec 15 '24	Option Exercise	0.00	10,204	0	27,357	Dec 16 05:40 PM
CHAPLIN ANN C	General Counsel&Corp Secretary	Dec 16 '24	Sale	158.12	2,587	409,056	19,739	Dec 16 05:40 PM
Palkhiwala Akash J.	CFO & COO	Dec 15 '24	Option Exercise	0.00	17,873	0	77,746	Dec 16 05:40 PM
ROGERS ALEXANDER H	President QTL & Global Affairs	Dec 15 '24	Option Exercise	0.00	13,030	0	45,802	Dec 16 05:39 PM
THOMPSON JAMES H	Chief Technology Officer	Dec 15 '24	Option Exercise	0.00	20,530	0	251,216	Dec 16 05:39 PM
ANN CHAPLIN	Officer	Dec 16 '24	Proposed Sale	158.12	2,587	409,056		Dec 16 04:15 PM
CHAPLIN ANN C	General Counsel&Corp Secretary	Dec 10 '24	Sale	160.59	7,717	1,239,288	17,153	Dec 11 05:33 PM
ROGERS ALEXANDER H	President QTL & Global Affairs	Dec 10 '24	Sale	160.59	10,373	1,665,781	33,383	Dec 11 05:33 PM
ANN CHAPLIN	Officer	Dec 10 '24	Proposed Sale	160.59	7,717	1,239,288		Dec 10 04:04 PM
ALEXANDER H ROGERS	Officer	Dec 10 '24	Proposed Sale	160.59	10,373	1,665,780		Dec 10 04:02 PM
Palkhiwala Akash J.	CFO & COO	Dec 05 '24	Sale	161.54	3,000	484,617	48,778	Dec 06 04:18 PM
Akash Palkhiwala	Chief Financial Officer	Dec 05 '24	Proposed Sale	160.39	3,000	481,170		Dec 05 05:35 PM
MARTIN NEIL	SVP, Finance and CAO	Nov 20 '24	Option Exercise	0.00	2,275	0	2,369	Nov 21 05:36 PM
MARTIN NEIL	SVP, Finance and CAO	Nov 21 '24	Sale	155.00	1,304	202,120	94	Nov 21 05:36 PM
NEIL A MARTIN	Officer	Nov 21 '24	Proposed Sale	155.00	1,304	202,120		Nov 21 04:03 PM
Palkhiwala Akash J.	CFO & COO	Nov 14 '24	Sale	163.78	3,000	491,349	51,778	Nov 15 04:12 PM
Akash Palkhiwala	Chief Financial Officer	Nov 14 '24	Proposed Sale	163.97	3,000	491,910		Nov 14 05:36 PM
THOMPSON JAMES H	Chief Technology Officer	Nov 08 '24	Sale	172.09	8,000	1,376,720	211,321	Nov 12 04:06 PM
JAMES H THOMPSON	Officer	Nov 08 '24	Proposed Sale	172.09	8,000	1,376,720		Nov 08 04:24 PM
CHAPLIN ANN C	General Counsel&Corp Secretary	Nov 01 '24	Option Exercise	0.00	5,812	0	15,918	Nov 04 04:15 PM
CHAPLIN ANN C	General Counsel&Corp Secretary	Nov 04 '24	Sale	165.06	1,901	313,779	12,007	Nov 04 04:15 PM
ANN CHAPLIN	Officer	Nov 04 '24	Proposed Sale	165.06	1,901	313,779		Nov 04 04:04 PM
THOMPSON JAMES H	Chief Technology Officer	Oct 01 '24	Option Exercise	0.00	9,575	0	222,939	Oct 02 04:56 PM
THOMPSON JAMES H	Chief Technology Officer	Oct 01 '24	Sale	169.80	8,000	1,358,400	213,364	Oct 02 04:56 PM
ROGERS ALEXANDER H	President QTL & Global Affairs	Oct 01 '24	Option Exercise	0.00	5,319	0	37,190	Oct 02 04:55 PM
ROGERS ALEXANDER H	President QTL & Global Affairs	Oct 02 '24	Sale	166.15	3,245	539,157	32,231	Oct 02 04:55 PM
Palkhiwala Akash J.	CFO & COO	Oct 01 '24	Option Exercise	0.00	5,107	0	56,544	Oct 02 04:55 PM
Palkhiwala Akash J.	CFO & COO	Oct 01 '24	Sale	165.95	3,000	497,848	51,437	Oct 02 04:55 PM
AMON CRISTIANO R	President & CEO	Oct 01 '24	Option Exercise	0.00	17,022	0	249,777	Oct 02 04:55 PM
ACE HEATHER S	Chief Human Resources Officer	Oct 01 '24	Option Exercise	0.00	2,926	0	28,919	Oct 02 04:55 PM
ALEXANDER H ROGERS	Officer	Oct 02 '24	Proposed Sale	166.15	3,245	539,157		Oct 02 04:03 PM
Akash Palkhiwala	Chief Financial Officer	Oct 01 '24	Proposed Sale	165.78	3,000	497,340		Oct 01 05:03 PM
JAMES H THOMPSON	Officer	Oct 01 '24	Proposed Sale	169.80	8,000	1,358,400		Oct 01 04:05 PM
MARTIN NEIL	SVP, Finance and CAO	Sep 05 '24	Sale	163.08	774	126,224	94	Sep 06 04:13 PM
NEIL A MARTIN	Officer	Sep 05 '24	Proposed Sale	163.08	774	126,224		Sep 05 04:02 PM
Palkhiwala Akash J.	CFO & COO	Sep 03 '24	Sale	165.99	3,000	497,980	54,437	Sep 04 04:07 PM
THOMPSON JAMES H	Chief Technology Officer	Sep 03 '24	Sale	171.72	8,000	1,373,760	221,987	Sep 04 04:06 PM
Akash Palkhiwala	Chief Financial Officer	Sep 03 '24	Proposed Sale	163.24	3,000	489,720		Sep 03 05:18 PM
JAMES H THOMPSON	Officer	Sep 03 '24	Proposed Sale	171.72	8,000	1,373,760		Sep 03 04:08 PM
MARTIN NEIL	SVP, Finance and CAO	Aug 20 '24	Option Exercise	0.00	1,183	0	1,277	Aug 21 04:22 PM
Palkhiwala Akash J.	CFO & COO	Aug 08 '24	Sale	162.89	3,000	488,662	57,437	Aug 09 04:05 PM
THOMPSON JAMES H	Chief Technology Officer	Aug 08 '24	Sale	164.40	4,539	746,212	0	Aug 09 04:05 PM
Akash Palkhiwala	Chief Financial Officer	Aug 08 '24	Proposed Sale	164.95	3,000	494,850		Aug 08 05:01 PM
THOMPSON JAMES H	Chief Technology Officer	Aug 02 '24	Sale	160.50	8,000	1,284,000	229,987	Aug 05 05:03 PM
JAMES H THOMPSON	Officer	Aug 02 '24	Proposed Sale	160.50	8,000	1,284,000		Aug 02 04:01 PM
Palkhiwala Akash J.	CFO & COO	Jul 05 '24	Sale	205.61	3,000	616,815	60,343	Jul 08 05:39 PM
THOMPSON JAMES H	Chief Technology Officer	Jul 01 '24	Sale	199.47	8,000	1,595,760	237,893	Jul 01 04:38 PM
THOMPSON JAMES H	Chief Technology Officer	Jun 03 '24	Sale	209.61	8,000	1,676,880	245,893	Jun 04 04:07 PM
Palkhiwala Akash J.	CFO & COO	Jun 03 '24	Sale	205.77	3,000	617,299	63,343	Jun 04 04:07 PM
MARTIN NEIL	SVP, Finance and CAO	May 20 '24	Option Exercise	0.00	2,253	0	2,253	May 22 05:38 PM
MARTIN NEIL	SVP, Finance and CAO	May 21 '24	Sale	196.11	1,116	218,859	358	May 22 05:38 PM
MARTIN NEIL	SVP, Finance and CAO	May 22 '24	Sale	202.13	358	72,362	0	May 22 05:38 PM
Smit Neil	Director	May 21 '24	Sale	200.94	3,069	616,670	0	May 21 07:34 PM
AMON CRISTIANO R	President & CEO	May 15 '24	Sale	190.01	8,100	1,539,081	0	May 16 05:19 PM
ACEVEDO SYLVIA	Director	May 10 '24	Sale	181.52	744	135,074	0	May 13 04:53 PM
AMON CRISTIANO R	President & CEO	May 09 '24	Sale	181.00	8,100	1,466,100	8,100	May 10 04:29 PM
Palkhiwala Akash J.	CFO & COO	May 09 '24	Sale	180.69	3,000	542,055	66,343	May 10 04:29 PM
ACEVEDO SYLVIA	Director	May 03 '24	Sale	178.21	2,056	366,400	54	May 06 04:24 PM
THOMPSON JAMES H	Chief Technology Officer	May 03 '24	Sale	182.00	8,000	1,456,000	253,893	May 03 05:54 PM
Palkhiwala Akash J.	CFO & COO	Apr 04 '24	Sale	173.49	3,000	520,480	69,343	Apr 04 07:35 PM
THOMPSON JAMES H	Chief Technology Officer	Apr 01 '24	Sale	168.27	8,000	1,346,160	261,893	Apr 02 04:13 PM
ACEVEDO SYLVIA	Director	Mar 10 '24	Option Exercise	0.00	2,056	0	2,110	Mar 11 05:10 PM
Henderson Jeffrey William	Director	Mar 10 '24	Option Exercise	0.00	2,056	0	6,408	Mar 11 05:09 PM
Johnson Gregory N	Director	Mar 10 '24	Option Exercise	0.00	2,056	0	3,147	Mar 11 05:09 PM
LIVERMORE ANN M	Director	Mar 10 '24	Option Exercise	0.00	2,056	0	32,873	Mar 11 05:08 PM
MCLAUGHLIN MARK D	Director	Mar 10 '24	Option Exercise	0.00	2,056	0	23,428	Mar 11 05:08 PM
Miller Jamie S	Director	Mar 10 '24	Option Exercise	0.00	2,056	0	4,159	Mar 11 05:08 PM
Palkhiwala Akash J.	CFO & COO	Mar 07 '24	Sale	175.02	7,000	1,225,118	72,343	Mar 11 04:54 PM
AMON CRISTIANO R	President & CEO	Mar 07 '24	Sale	169.60	8,100	1,373,760	16,200	Mar 08 04:10 PM
MARTIN NEIL	SVP, Finance and CAO	Mar 05 '24	Sale	160.64	689	110,680	0	Mar 05 06:18 PM
THOMPSON JAMES H	Chief Technology Officer	Mar 01 '24	Sale	159.39	8,000	1,275,120	269,893	Mar 01 06:40 PM
AMON CRISTIANO R	President & CEO	Mar 01 '24	Sale	159.50	8,100	1,291,950	24,300	Mar 01 06:25 PM
MARTIN NEIL	SVP, Finance and CAO	Feb 20 '24	Option Exercise	0.00	1,172	0	1,513	Feb 21 04:57 PM
MARTIN NEIL	SVP, Finance and CAO	Feb 21 '24	Sale	149.83	371	55,587	689	Feb 21 04:57 PM
AMON CRISTIANO R	President & CEO	Jan 19 '24	Sale	149.50	8,100	1,210,950	32,400	Jan 19 05:28 PM

HALO

Halozyme Therapeutics Inc

FGEN

FibroGen Inc

QCOM

Qualcomm, Inc

Upgrade your FINVIZ experience